Fred Hutchinson Cancer Research Center
University of Washington Cancer Consortium / SCCA
Seattle, WA
Accepting patients
Talisman
A Phase 2, Open-label, Randomized Study to Evaluate Prophylactic Interventions on Talquetamab-related Oral Toxicity
- Bispecific Antibody
- GPRC5D
- Randomization
- Phase 2
Accepting patients
QUINTESSENTIAL
Phase 2 Study of BMS-986393, a GPRC5D-directed CART-Cell Therapy, in Participants with Relapsed or Refractory Multiple Myeloma
- CAR T Cell
- GPRC5D
- Phase 2
Accepting patients
MagnetisMM-30
A Phase 1B, Open-Label Study of Elranatamab in Combination with Iberdomide in Participants with Relapsed Refractory Multiple Myeloma
- Bispecific Antibody
- Bispecific T Cell Engager (BiTE)
- BCMA
- CD3
- Phase 1
- Has results
Accepting patients
Sonrotoclax (BGB-11417)
A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma
- BCL-2 Inhibitor
- Phase 1/2
- Has results
Not currently accepting
Iberdomide vs. Observation Post Ide-Cel CAR-T
Iberdomide Versus Observation Off Therapy After Idecabtagene Vicleucel CAR-T for Multiple Myeloma
- CELMoD
- Randomization
- Maintenance
- Phase 2
Accepting patients
DoMMino-1
A Phase II, Open-Label, Multicenter Study of Inobrodib in Combination With Pomalidomide and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma
- CBP (CREB-binding Protein) Inhibitor
- Bromodomain Inhibitor
- P300 Inhibitor
- Phase 2
Accepting patients
Linvoseltamab De-Escalation
Pharmacodynamically Monitored Linvoseltamab Dosing De-Escalation in Relapsed Multiple Myeloma
- Bispecific Antibody
- CD3
- BCMA
- Phase 1/2
- Proteasome Inhibitor
- Minimal Residual Disease (MRD)
- Randomization
- Phase 2
Accepting patients
OPN-662
A Phase 1b, Dose Escalation/Dose Expansion, Multicenter, Open-Label Study to Assess the Safety and Tolerability of OPN-6602 Monotherapy and in Combination With Dexamethasone in Subjects With Relapsed and/or Refractory Multiple Myeloma
- BET Inhibitor
- Phase 1
- Has results
Not yet accepting
²¹¹At-OKT10-B10 with Fludarabine
²¹¹At-OKT10-B10 and Fludarabine Alone or in Combination With Cyclophosphamide and Low-Dose TBI Before Donor Stem Cell Transplant for the Treatment of Newly Diagnosed, Recurrent, or Refractory High-Risk Multiple Myeloma
- Monoclonal Antibody
- Allogeneic Stem Cell Transplant
- CD38
- High Risk
- Phase 1
2 hidden based on your filters.Show All